LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Benzo[a]phenoselenazine-based NIR photosensitizer for tumor-targeting photodynamic therapy via lysosomal-disruption pathway

Photo from wikipedia

Abstract The ultimate goal of cancer therapy is to develop antitumor agents that will destroy selectively tumor cells while sparing the health cell of the patient. Herein, we reported a… Click to show full abstract

Abstract The ultimate goal of cancer therapy is to develop antitumor agents that will destroy selectively tumor cells while sparing the health cell of the patient. Herein, we reported a novel tumor-specific and lysosome dual-targeted NIR photosensitizer, Se-Biotin, by conjugating a biotin ligand into benzo[a]phenoselenazinium derivative dye for selective destruction of tumor cells. Attractively, co-culture model showed that Se-Biotin could selectively target to and retain in biotin receptor-overexpressed tumor cells, which as a result significantly minimized the side effects toward normal cells. As confirmed by the in vitro anticancer mechanism, after cellular internalization, upon irradiation, the effective1O2 generation (ΦΔ = 0.69)severely disrupted the lysosomalintegrity and subsequently led to apoptotic cell death. Benefiting from these merits, Se-Biotin successfully achieved a superior anticancer performance with the IC50 as low as 85 nM, only under a low light dose irradiation (12 J/cm2, 660 nm). Therefore, these result demonstrated that Se-Biotin will be a promising PDT agent for targeted cancer photodynamic therapy.

Keywords: therapy; tumor cells; tumor; nir photosensitizer; photodynamic therapy

Journal Title: Dyes and Pigments
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.